

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
16 January 2003 (16.01.2003)

PCT

(10) International Publication Number  
**WO 03/004033 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/485**,  
9/00, A61P 25/04

W.; 8861 Three Chimneys Drive East, Germantown, TN  
38138 (US).

(21) International Application Number: PCT/US02/21403

(74) Agents: SUPERKO, Colleen et al.; Hale and Dorr LLP,  
60 State Street, Boston, MA 02109 (US).

(22) International Filing Date: 3 July 2002 (03.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/303,357 6 July 2001 (06.07.2001) US  
60/329,352 15 October 2001 (15.10.2001) US  
60/329,426 15 October 2001 (15.10.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: PENWEST PHARMACEUTICALS COM-  
PANY [US/US]; 2981 Route 22, Patterson, NY 12563-  
9770 (US).


(72) Inventors: BAICHWAL, Anand, R.; 5 Kendell Drive,  
Wappingers Falls, NY 12590 (US). KAO, Huai-Hung; 137  
Colony Lane, Syosset, NY 11791 (US). MCCALL, Troy,

Published:  
— with international search report

[Continued on next page]

(54) Title: SUSTAINED RELEASE FORMULATIONS OF OXYMORPHONE

MEAN PLASMA OXYMORPHONE CONCENTRATIONS VERSUS TIME - LINEAR SCALE



(57) Abstract: Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.

WO 03/004033 A1

ATTORNEY DOCKET NUMBER: 6750-264-999  
SERIAL NUMBER: 10/731,678  
REFERENCE: B54

WO 03/004033 A1

---



*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## **Sustained Release Formulations of Oxymorphone**

### **Related Applications**

This application claims priority to US Provisional Application No. 60/329,426 filed October 15, 2001, US Provisional Application No. 60/329,352 filed October 15, 5 2001, and to US Provisional Application No. 60/303,357 filed July 6, 2001, the disclosures of which are incorporated by reference herein in their entirety.

### **Field of the Invention**

The invention provides sustained release formulations of oxymorphone and pharmaceutically acceptable salts thereof; methods for making the sustained release 10 formulations of oxymorphone and pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of oxymorphone and pharmaceutically acceptable salts thereof to treat patients suffering from pain.

### **Background of the Invention**

Pain is the most frequently reported symptom and it is a common clinical 15 problem which confronts the clinician. Many millions of people in the United States suffer from severe pain that is chronically undertreated or inappropriately managed. The clinical usefulness of the analgesic properties of opioids has been recognized for centuries, and morphine and its derivatives have been widely used for analgesia for decades in a variety of clinical pain states.

20 Oxymorphone HCl (14-hydroxydihydromorphinone hydrochloride) is a semi-synthetic phenanthrene-derivative opioid agonist, used in the treatment of acute and chronic pain, with analgesic efficacy comparable to other opioid analgesics. Oxymorphone is currently marketed as an injection (1 mg/ml in 1 ml ampules; 1.5 mg/ml in 1 ml ampules; 1.5 mg/ml in 10 ml multiple dose vials) for intramuscular, 25 subcutaneous, and intravenous administration, and as 5 mg rectal suppositories. At one time, a 10 mg oral immediate release tablet formulation of oxymorphone HCl was marketed. Oxymorphone HCl is metabolized principally in the liver and undergoes conjugation with glucuronic acid and reduction to 6 alpha and beta hydroxy epimers.

An important goal of analgesic therapy is to achieve continuous relief of chronic 30 pain. Regular administration of an analgesic is generally required to ensure that the next dose is given before the effects of the previous dose have worn off. Compliance with opioids increases as the required dosing frequency decreases. Non-compliance results in suboptimal pain control and poor quality of life outcomes. Scheduled rather than "as

needed" administration of opioids is currently recommended in guidelines for their use in treating chronic non-malignant pain. Unfortunately, evidence from prior clinical trials and clinical experience suggests that the short duration of action of immediate release oxymorphone would necessitate 4-hourly administrations in order to maintain optimal  
5 levels of analgesia in patients with chronic pain. Moreover, immediate release oxymorphone exhibits low oral bioavailability, because oxymorphone is extensively metabolized in the liver.

There is a need in the art for new formulations of oxymorphone that require less frequent dosing. The invention is directed to these, as well as other, important ends.

10

### Summary of the Invention

The invention provides compositions comprising oxymorphone or a pharmaceutically acceptable salt thereof and a sustained release delivery system, where the sustained release delivery system comprises at least one hydrophilic compound, at least one cross-linking agent (which may be cationic) and at least one pharmaceutical  
15 diluent. The sustained release delivery system may further comprise one or more additional hydrophobic polymers or cross-linking compounds. The compositions may optionally comprise an outer coating comprising at least one water insoluble compound, and optionally one or more plasticizers and/or water soluble compounds.

The invention provides compositions comprising an inner core and an outer  
20 sustained release coating, where the inner core comprises oxymorphone or a pharmaceutically acceptable salt thereof and the outer sustained release coating comprises at least one water insoluble compound. The outer sustained release coating may optionally further comprise one or more plasticizers and/or water soluble compounds.

25 The invention provides methods for treating pain in patients by administering an effective amount of any of the compositions of the invention. The pain may be moderate to severe, and may be acute or chronic.

The invention also provides methods for making such compositions.

These and other aspects of the invention are described in detail herein.

30

### Brief Description of the Figure

Figure 1 is a linear scale graph, without standard deviations, showing the mean oxymorphone plasma concentration versus time for patients treated with the sustained release oxymorphone tablets of the invention after fasting (A), for patients treated with sustained release oxymorphone tablets of the invention after a high fat meal (B), for

patients treated with an oxymorphone solution after fasting (C), and for patients treated with an oxymorphone solution after a high fat meal (D).

### Detailed Description of the Invention

To overcome the difficulties associated with the very low bioavailability of the oral immediate release formulation of oxymorphone and with a 4 hourly dosing frequency of oxymorphone, the invention provides an oral sustained release formulation of oxymorphone comprising an analgesically effective amount of oxymorphone or a pharmaceutically acceptable salt thereof. The bioavailability of the oral sustained release formulations of the invention is sufficiently high that the sustained release formulations can be used to treat patients suffering from pain with only once or twice daily dosing.

The invention provides compositions comprising oxymorphone or a pharmaceutically acceptable salt thereof and a sustained release delivery system, wherein the sustained release delivery system comprises (i) at least one hydrophilic compound, at least one cross-linking agent, and at least one pharmaceutical diluent; (ii) at least one hydrophilic compound, at least one cross-linking agent, at least one pharmaceutical diluent, and at least one hydrophobic polymer; (iii) at least one hydrophilic compound, at least one cross-linking agent, at least one pharmaceutical diluent, and at least one cationic cross-linking agent different from the first cross-linking agent; (iv) at least one hydrophilic compound, at least one cross-linking agent, at least one pharmaceutical diluent, at least one cationic cross-linking compound different from the first cross-linking agent, and at least one hydrophobic polymer; (v) at least one hydrophilic compound, at least one cationic cross-linking compound, and at least one pharmaceutical diluent; or (vi) at least one hydrophilic compound, at least one cationic cross-linking compound, at least one pharmaceutical diluent, and at least one hydrophobic compound.

The oxymorphone may be homogeneously dispersed in the sustained release delivery system. Preferably, the oxymorphone or pharmaceutically acceptable salt thereof may be present in the composition in an amount of about 1 mg to about 200 mg, more preferably in an amount of about 1 mg to about 100 mg, even more preferably in an amount of about 5 mg to about 80 mg. Preferably, the sustained release delivery system may be present in the composition in an amount from about 80 mg to about 420 mg, more preferably from about 80 mg to about 360 mg, even more preferably from about 80 mg to about 200 mg. "Oxymorphone" includes oxymorphone, metabolites thereof, derivatives thereof, and/or pharmaceutically acceptable salts thereof. Metabolites of

oxymorphone include, for example, 6-hydroxy-oxymorphone (e.g., 6- $\alpha$ -hydroxy-oxymorphone and/or 6- $\beta$ -hydroxy-oxymorphone).

Oxymorphone may be in the form of any pharmaceutically acceptable salt known in the art. Exemplary pharmaceutically acceptable salts include hydrochloric, sulfuric, nitric, phosphoric, hydrobromic, maleric, malic, ascorbic, citric, tartaric, pamoic, lauric, stearic, palmitic, oleic, myristic, lauryl sulfuric, naphthalenesulfonic, linoleic, linolenic acid, and the like. The hydrochloride salt of oxymorphone is preferred.

The sustained release delivery system comprises at least one hydrophilic compound. The hydrophilic compound preferably forms a gel matrix that releases the oxymorphone or the pharmaceutically acceptable salt thereof at a sustained rate upon exposure to liquids. The rate of release of the oxymorphone or the pharmaceutically acceptable salt thereof from the gel matrix depends on the drug's partition coefficient between the components of the gel matrix and the aqueous phase within the gastrointestinal tract. In the compositions of the invention, the weight ratio of oxymorphone to hydrophilic compound is generally in the range of about 1:0.5 to about 1:25, preferably in the range of about 1:0.5 to about 1:20. The sustained release delivery system generally comprises the hydrophilic compound in an amount of about 20% to about 80% by weight, preferably in an amount of about 20% to about 60% by weight, more preferably in an amount of about 40% to about 60% by weight, still more preferably in an amount of about 50% by weight.

The hydrophilic compound may be any known in the art. Exemplary hydrophilic compounds include gums, cellulose ethers, acrylic resins, polyvinyl pyrrolidone, protein-derived compounds, and mixtures thereof. Exemplary gums include heteropolysaccharide gums and homopolysaccharide gums, such as xanthan, tragacanth, pectins, acacia, karaya, alginates, agar, guar, hydroxypropyl guar, carrageenan, locust bean gums, and gellan gums. Exemplary cellulose ethers include hydroxyalkyl celluloses and carboxyalkyl celluloses. Preferred cellulose ethers include hydroxyethyl celluloses, hydroxypropyl celluloses, hydroxypropylmethyl-celluloses, carboxy methylcelluloses, and mixtures thereof. Exemplary acrylic resins include polymers and copolymers of acrylic acid, methacrylic acid, methyl acrylate and methyl methacrylate. In some embodiments, the hydrophilic compound is preferably a gum, more preferably a heteropolysaccharide gum, most preferably a xanthan gum or derivative thereof. Derivatives of xanthan gum include, for example, deacylated xanthan gum, the carboxymethyl esters of xanthan gum, and the propylene glycol esters of xanthan gum.

In another embodiment, the sustained release delivery system may further comprise at least one cross-linking agent. The cross-linking agent is preferably a compound that is capable of cross-linking the hydrophilic compound to form a gel matrix in the presence of liquids. As used herein, "liquids" includes, for example,

5 gastrointestinal fluids and aqueous solutions, such as those used for *in vitro* dissolution testing. The sustained release delivery system generally comprises the cross-linking agent in an amount of about 0.5% to about 80% by weight, preferably in an amount of about 2% to about 54% by weight, more preferably in an amount of about 20% to about 30% by weight more, still more preferably in an amount of about 25% by weight.

10 Exemplary cross-linking agents include homopolysaccharides. Exemplary homopolysaccharides include galactomannan gums, such as guar gum, hydroxypropyl guar gum, and locust bean gum. In some embodiments, the cross-linking agent is preferably a locust bean gum or a guar gum. In other embodiments, the cross-linking agents may be alginic acid derivatives or hydrocolloids.

15 When the sustained release delivery system comprises at least one hydrophilic compound and at least one cross-linking agent, the ratio of hydrophilic compound to cross-linking agent may be from about 1:9 to about 9:1, preferably from about 1:3 to about 3:1.

The sustained release delivery system of the invention may comprise one or more  
20 cationic cross-linking compounds. Cationic cross-linking compound may be used instead of or in addition to the cross-linking agent. The cationic cross-linking compounds may be used in an amount sufficient to cross-link the hydrophilic compound to form a gel matrix in the presence of liquids. The cationic cross-linking compound is present in the sustained release delivery system in an amount of about 0.5% to about  
25 30% by weight, preferably from about 5% to about 20% by weight.

Exemplary cationic cross-linking compounds include monovalent metal cations, multivalent metal cations, and inorganic salts, including alkali metal and/or alkaline earth metal sulfates, chlorides, borates, bromides, citrates, acetates, lactates, and mixtures thereof. For example, the cationic cross-linking compound may be one or more of  
30 calcium sulfate, sodium chloride, potassium sulfate, sodium carbonate, lithium chloride, tripotassium phosphate, sodium borate, potassium bromide, potassium fluoride, sodium bicarbonate, calcium chloride, magnesium chloride, sodium citrate, sodium acetate, calcium lactate, magnesium sulfate, sodium fluoride, or mixtures thereof.

When the sustained release delivery system comprises at least one hydrophilic compound and at least one cationic cross-linking compound, the ratio of hydrophilic compound to cationic cross-linking compound may be from about 1:9 to about 9:1, preferably from about 1:3 to about 3:1.

- 5        Two properties of desirable components of this system (e.g., the at least one hydrophilic compound and the at least one cross-linking agent; or the at least one hydrophilic compound and at least one cationic cross-linking compound) that form a gel matrix upon exposure to liquids are fast hydration of the compounds/agents and the ability to form a gel matrix having a high gel strength. These two properties, which are  
10        needed to achieve a slow release gel matrix, are maximized in the invention by the particular combination of compounds (e.g., the at least one hydrophilic compound and the at least one cross-linking agent; or the at least one hydrophilic compound and the at least one cationic cross-linking compound). For example, hydrophilic compounds (e.g., xanthan gum) have excellent water-wicking properties which provide fast hydration.  
15        The combination of hydrophilic compounds with materials that are capable of cross-linking the rigid helical ordered structure of the hydrophilic compound (e.g., cross-linking agents and/or cationic cross-linking compounds) thereby act synergistically to provide a higher than expected viscosity (i.e., high gel strength) of the gel matrix.

- The sustained release delivery system further comprises one or more  
20        pharmaceutical diluents known in the art. Exemplary pharmaceutical diluents include monosaccharides, disaccharides, polyhydric alcohols and mixtures thereof. Preferred pharmaceutical diluents include, for example, starch, lactose, dextrose, sucrose, microcrystalline cellulose, sorbitol, xylitol, fructose, and mixtures thereof. In other embodiments, the pharmaceutical diluent is water-soluble, such as lactose, dextrose,  
25        sucrose, or mixtures thereof. The ratio of pharmaceutical diluent to hydrophilic compound is generally from about 1:8 to about 8:1, preferably from about 1:3 to about 3:1. The sustained release delivery system generally comprises one or more pharmaceutical diluents in an amount of about 20% to about 80% by weight, preferably about 35% by weight. In other embodiments, the sustained release delivery system  
30        comprises one or more pharmaceutical diluents in an amount of about 40% to about 80% by weight.

      The sustained release delivery system of the invention may comprise one or more hydrophobic polymers. The hydrophobic polymers may be used in an amount sufficient to slow the hydration of the hydrophilic compound without disrupting it. For example,



the hydrophobic polymer may be present in the sustained release delivery system in an amount of about 0.5% to about 20% by weight, preferably in an amount of about 2% to about 10% by weight, more preferably in an amount of about 3% to about 7% by weight, still more preferably in an amount of about 5% by weight.

5 Exemplary hydrophobic polymers include alkyl celluloses (e.g., C<sub>1-6</sub> alkyl celluloses, carboxymethylcellulose), other hydrophobic cellulosic materials or compounds (e.g., cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate), polyvinyl acetate polymers (e.g., polyvinyl acetate phthalate), polymers or copolymers derived from acrylic and/or methacrylic acid esters, zein, waxes, shellac, hydrogenated  
10 vegetable oils, and mixtures thereof. The hydrophobic polymer is preferably methylcellulose, ethyl cellulose or propyl cellulose, more preferably ethyl cellulose.

The compositions of the invention may be further admixed with one or more wetting agents (such as polyethoxylated castor oil, polyethoxylated hydrogenated castor oil, polyethoxylated fatty acid from castor oil, polyethoxylated fatty acid from  
15 hydrogenated castor oil) one or more lubricants (such as magnesium stearate, sodium stearyl fumarate, and the like), one or more buffering agents, one or more colorants, and/or other conventional ingredients.

In other embodiments, the invention provides oral sustained release solid dosage formulations comprising from about 1 mg to 200 mg oxymorphone hydrochloride,  
20 preferably from about 5 mg to about 80 mg oxymorphone hydrochloride; and about 80 mg to about 200 mg of a sustained release delivery system, preferably from about 120 mg to about 200 mg of a sustained release delivery system, more preferably about 160 mg of a sustained release delivery system; where the sustained release delivery system comprises about 8.3 to about 41.7% locust bean gum, preferably about 25% locust bean  
25 gum; about 8.3 to about 41.7% xanthan gum, preferably about 25% xanthan gum; about 20 to about 55% dextrose, preferably about 35% dextrose; about 5 to about 20% calcium sulfate dihydrate, preferably about 10% calcium sulfate dihydrate; and about 2 to 10% ethyl cellulose, preferably about 5% ethyl cellulose.

In other embodiments, the invention provides oral sustained release solid dosage  
30 formulations comprising from about 1 mg to 200 mg oxymorphone hydrochloride, preferably from about 5 mg to about 80 mg oxymorphone hydrochloride; and about 200 mg to about 420 mg of a sustained release delivery system, preferably from about 300 mg to about 420 mg of a sustained release delivery system, more preferably about 360 mg of a sustained release delivery system; where the sustained release delivery system

comprises about 8.3 to about 41.7% locust bean gum, preferably about 25% locust bean gum; about 8.3 to about 41.7% xanthan gum, preferably about 25% xanthan gum; about 20 to about 55% dextrose, preferably about 35% dextrose; about 5 to about 20% calcium sulfate dihydrate, preferably about 10% calcium sulfate dihydrate; and about 2 to 10% ethyl cellulose, preferably about 5% ethyl cellulose.

The sustained release formulations of oxymorphone are preferably orally administrable solid dosage formulations which may be, for example, tablets, capsules comprising a plurality of granules, sublingual tablets, powders, or granules; preferably tablets. The tablets may be an enteric coating or a hydrophilic coating.

The sustained release delivery system in the compositions of the invention may be prepared by dry granulation or wet granulation, before the oxymorphone or pharmaceutically acceptable salt thereof is added, although the components may be held together by an agglomeration technique to produce an acceptable product. In the wet granulation technique, the components (e.g., hydrophilic compounds, cross-linking agents, pharmaceutical diluents, cationic cross-linking compounds, hydrophobic polymers, etc.) are mixed together and then moistened with one or more liquids (e.g., water, propylene glycol, glycerol, alcohol) to produce a moistened mass which is subsequently dried. The dried mass is then milled with conventional equipment into granules of the sustained release delivery system. Thereafter, the sustained release delivery system is mixed in the desired amounts with the oxymorphone or the pharmaceutically acceptable salt thereof and, optionally, one or more wetting agents, one or more lubricants, one or more buffering agents, one or more coloring agents, or other conventional ingredients, to produce a granulated composition. The sustained release delivery system and the oxymorphone may be blended with, for example, a high shear mixer. The oxymorphone is preferably finely and homogeneously dispersed in the sustained release delivery system. The granulated composition, in an amount sufficient to make a uniform batch of tablets, is subjected to tableting in a conventional production scale tableting machine at normal compression pressures, i.e., about 2,000-16,000 psi. The mixture should not be compressed to a point where there is subsequent difficulty with hydration upon exposure to liquids.

The average particle size of the granulated composition is from about 50  $\mu\text{m}$  to about 400  $\mu\text{m}$ , preferably from about 185  $\mu\text{m}$  to about 265  $\mu\text{m}$ . The average density of the granulated composition is from about 0.3 g/ml to about 0.8 g/ml, preferably from about 0.5 g/ml to about 0.7 g/ml. The tablets formed from the granulations are generally

from about 6 to about 8 kg hardness. The average flow of the granulations are from about 25 to about 40 g/sec.

In other embodiments, the invention provides sustained release coatings over an inner core comprising oxymorphone or a pharmaceutically acceptable salt thereof. For example, the inner core comprising oxymorphone or a pharmaceutically acceptable salt thereof may be coated with a sustained release film which, upon exposure to liquids, releases the oxymorphone or the pharmaceutically acceptable salt thereof from the core at a sustained rate.

In one embodiment, the sustained release coating comprises at least one water insoluble compound. The water insoluble compound is preferably a hydrophobic polymer. The hydrophobic polymer may be the same as or different from the hydrophobic polymer used in the sustained release delivery system. Exemplary hydrophobic polymers include alkyl celluloses (e.g., C<sub>1-6</sub> alkyl celluloses, carboxymethylcellulose), other hydrophobic cellulosic materials or compounds (e.g., cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate), polyvinyl acetate polymers (e.g., polyvinyl acetate phthalate), polymers or copolymers derived from acrylic and/or methacrylic acid esters, zein, waxes (alone or in admixture with fatty alcohols), shellac, hydrogenated vegetable oils, and mixtures thereof. The hydrophobic polymer is preferably, methyl cellulose, ethyl cellulose or propyl cellulose, more preferably ethyl cellulose. The sustained release formulations of the invention may be coated with a water insoluble compound to a weight gain from about 1 to about 20% by weight.

The sustained release coating may further comprise at least one plasticizer such as triethyl citrate, dibutyl phthalate, propylene glycol, polyethylene glycol, or mixtures thereof. The sustained release coating may also contain at least one water soluble compound, such as polyvinylpyrrolidones, hydroxypropylmethylcelluloses, or mixtures thereof. The sustained release coating may comprise at least one water soluble compound in an amount from about 1% to about 6% by weight, preferably in an amount of about 3% by weight.

The sustained release coating may be applied to the oxymorphone core by spraying an aqueous dispersion of the water insoluble compound onto the oxymorphone core. The oxymorphone core may be a granulated composition made, for example, by dry or wet granulation of mixed powders of oxymorphone and at least one binding agent; by coating an inert bead with oxymorphone and at least one binding agent; or by

spheronizing mixed powders of oxymorphone and at least one spheronizing agent. Exemplary binding agents include hydroxypropylmethylcelluloses. Exemplary spheronizing agents include microcrystalline celluloses. The inner core may be a tablet made by compressing the granules or by compressing a powder comprising

5 oxymorphone or the pharmaceutically acceptable salt thereof.

In other embodiments, the compositions comprising oxymorphone or a pharmaceutically acceptable salt thereof and a sustained release delivery system, as described herein, are coated with a sustained release coating, as described herein. In still other embodiments, the compositions comprising oxymorphone or a pharmaceutically acceptable salt thereof and a sustained release delivery system, as described herein, are coated with a hydrophobic polymer, as described herein. In still other embodiments, the compositions comprising oxymorphone or a pharmaceutically acceptable salt thereof and a sustained release delivery system, as described herein, are coated with an enteric coating, such as cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, 15 polyvinylacetate phthalate, methacrylic acid copolymer, shellac, hydroxypropylmethylcellulose succinate, cellulose acetate trimellitate, or mixtures thereof. In still other embodiments, the compositions comprising oxymorphone or a pharmaceutically acceptable salt thereof and a sustained release delivery system, as described herein, are coated with a hydrophobic polymer, as described herein, and 20 further coated with an enteric coating, as described herein. In any of the embodiments described herein, the compositions comprising oxymorphone or a pharmaceutically acceptable salt thereof and a sustained release delivery system, as described herein, may optionally be coated with a hydrophilic coating which may be applied above or beneath the sustained release film, above or beneath the hydrophobic coating, and/or above or 25 beneath the enteric coating. Preferred hydrophilic coatings comprise hydroxypropylmethylcellulose.

The invention provides methods for treating pain by administering an effective amount of the sustained release formulations of oxymorphone to a patient in need thereof. An effective amount is an amount sufficient to eliminate all pain or to alleviate the pain (i.e., reduce the pain compared to the pain present prior to administration of the 30 oxymorphone sustained release formulation). "Sustained release" means that the oxymorphone or pharmaceutically acceptable salt thereof is released from the formulation at a controlled rate so that therapeutically beneficial blood levels (but below toxic levels) of the oxymorphone or pharmaceutically acceptable salt thereof are

maintained over an extended period of time. The sustained release formulations of oxymorphone are administered in an amount sufficient to alleviate pain for an extended period of time, preferably about 8 hours to about 24 hours, more preferably for a period of about 12 hours to about 24 hours. The oxymorphone sustained release oral solid dosage formulations of the invention may be administered one to four times a day, preferably once or twice daily, more preferably once daily. The pain may be minor to moderate to severe, and is preferably moderate to severe. The pain may be acute or chronic. The pain may be associated with, for example, cancer, autoimmune diseases, infections, surgical traumas, accidental traumas or osteoarthritis. The patient may be an animal, preferably a mammal, more preferably a human.

In certain embodiments, upon oral ingestion of the oxymorphone sustained release formulation and contact of the formulation with gastrointestinal fluids, the sustained release formulation swells and gels to form a hydrophilic gel matrix from which the oxymorphone is released. The swelling of the gel matrix causes a reduction in the bulk density of the formulation and provides the buoyancy necessary to allow the gel matrix to float on the stomach contents to provide a slow delivery of the oxymorphone. The hydrophilic matrix, the size of which is dependent upon the size of the original formulation, can swell considerably and become obstructed near the opening of the pylorus. Since the oxymorphone is dispersed throughout the formulation (and consequently throughout the gel matrix), a constant amount of oxymorphone can be released per unit time *in vivo* by dispersion or erosion of the outer portions of the hydrophilic gel matrix. The process continues, with the gel matrix remaining bouyant in the stomach, until substantially all of the oxymorphone is released.

In certain embodiments, the chemistry of certain of the components of the formulation, such as the hydrophilic compound (e.g., xanthan gum), is such that the components are considered to be self-buffering agents which are substantially insensitive to the solubility of the oxymorphone and the pH changes along the length of the gastrointestinal tract. Moreover, the chemistry of the components is believed to be similar to certain known muco-adhesive substances, such as polycarbophil. Muco-adhesive properties are desirable for buccal delivery systems. Thus, the sustained release formulation can loosely interact with the mucin in the gastrointestinal tract and thereby provide another mode by which a constant rate of delivery of the oxymorphone is achieved.

The two phenomenon discussed above (buoyancy and muco-adhesive properties) are mechanisms by which the sustained release formulations of the invention can interact with the mucin and fluids of the gastrointestinal tract and provide a constant rate of delivery of the oxymorphone.

5           When measured by USP Procedure Drug Release USP 23 (incorporated by reference herein in its entirety), the sustained release formulations of the invention exhibit an *in vitro* dissolution rate of about 15% to about 50% by weight oxymorphone after 1 hour, about 45% to about 80% by weight oxymorphone after 4 hours, and at least about 80% by weight oxymorphone after 10 hours. The *in vitro* and *in vivo* release  
10 characteristics of the sustained release formulations of the invention may be modified using mixtures of one or more different water insoluble and/or water soluble compounds, using different plasticizers, varying the thickness of the sustained release film, including providing release-modifying compounds in the coating, and/or by providing  
passageways through the coating.

15           When administered orally to patients the sustained release formulations of the invention exhibit the following *in vivo* characteristics: (a) a peak plasma level of oxymorphone occurs within about 2 to about 6 hours after administration; (b) the duration of the oxymorphone analgesic effect is about 8 to about 24 hours; and (c) the relative oxymorphone bioavailability is about 0.5 to about 1.5 compared to an orally  
20 administered aqueous solution of oxymorphone.

While the compositions of the invention may be administered as the sole active pharmaceutical compound in the methods described herein, they can also be used in combination with one or more compounds which are known to be therapeutically effective against pain.

25           The invention also provides pharmaceutical kits comprising one or more containers filled with one or more of the compositions of the invention. The kits may further comprise other pharmaceutical compounds known in the art to be therapeutically effective against pain, and instructions for use.

#### Examples

30           The following examples are for purposes of illustration only and are not intended to limit the scope of the appended claims.

**Examples 1 and 2**

Two sustained release delivery systems were prepared by dry blending xanthan gum, locust bean gum, calcium sulfate dehydrate, and dextrose in a high speed mixed/granulator for 3 minutes. A slurry was prepared by mixing ethyl cellulose with alcohol. While running choppers/impellers, the slurry was added to the dry blended mixture, and granulated for another 3 minutes. The granulation was then dried to a LOD (loss on drying) of less than about 10% by weight. The granulation was then milled using 20 mesh screen. The relative quantities of the ingredients are listed in Table 1.

**Table 1**

Sustained Release Delivery System	Example 1	Example 2
Excipient	%	%
Locust Bean Gum, FCC	25.0	30.0
Xanthan Gum, NF	25.0	30.0
Dextrose, USP	35.0	40.0
Calcium Sulfate Dihydrate, NF	10.0	0.0
Ethylcellulose, NF	5.0	0.0
Alcohol, SD3A (Anhydrous) <sup>1</sup>	(10) <sup>1</sup>	(20.0) <sup>1</sup>
Total	100.0	100.0

10

1. Volatile, removed during processing

**Examples 3 to 7**

A series of tablets containing different amounts of oxymorphone hydrochloride were prepared using the sustained release delivery system of Example 1. The quantities of ingredients per tablet are listed in Table 2.

15

Table 2

	Ex. 3	Ex. 4	Ex. 5	Ex. 6	Ex. 7
Component	mg	mg	mg	mg	mg
Oxymorphone HCl, USP	5	10	20	40	80
Sustained release delivery system	160	160	160	160	160
Silicified microcrystalline cellulose, N.F.	20	20	20	20	20
Sodium stearyl fumarate, NF	2	2	2	2	2
Total weight	187	192	202	222	262
OPADRY® (colored)	7.48	7.68	8.08	8.88	10.48
OPADRY® (clear)	0.94	0.96	1.01	1.11	1.31

**Examples 8 and 9**

- Two batches of tablets were prepared as described above for Examples 1-7, using the sustained release delivery system of Example 1. One batch was formulated to provide relatively fast sustained release, the other batch was formulated to provide relatively slow sustained release. Compositions of the tablets are shown in Table 3.

Table 3

	Example 8 slow release	Example 9 fast release
Ingredients	mg/tablet	mg/tablet
Oxymorphone HCl, USP	20	20
Sustained Release Delivery System	360	160
Silicified Microcrystalline Cellulose, NF	20	20
Sodium stearyl fumarate, NF	4	2
Coating (color)	12.12	12.12
Total weight	416.12	214.12

- The tablets of Examples 8 and 9 were tested for *in vitro* release rate according to USP Procedure Drug Release USP 23. The results are shown in Table 4.

Table 4

Time (hr)	Example 8 slow release	Example 9 fast release
0.5	18.8%	21.3%



1	27.8%	32.3%
2	40.5%	47.4%
3	50.2%	58.5%
4	58.1%	66.9%
5	64.7%	73.5%
6	70.2%	78.6%
8	79.0%	86.0%
10	85.3%	90.6%
12	89.8%	93.4%

#### Example 10: Clinical Study

A clinical study was conducted to (1) assess the relative bioavailability (rate and extent of absorption) of oxymorphone sustained release (20 mg) (fast release formulation of Example 9) compared to oral solution oxymorphone (10 mg) under fasted conditions, (2) to assess the relative bioavailability of oxymorphone sustained release (20 mg) compared to oral solution oxymorphone (10 mg) under fed conditions, (3) to assess the relative bioavailability of oxymorphone sustained release (20 mg) fed compared to oxymorphone sustained release (20 mg) fasted, (4) to assess the relative bioavailability of oral solution oxymorphone fed compared to oral solution oxymorphone fasted, and (5) to assess the relative safety and tolerability of sustained release oxymorphone (20 mg) under fed and fasted conditions.

This study had a single-center, open-label, analytically blinded, randomized, four-way crossover design. Subjects randomized to Treatment A and Treatment C, as described below, were in a fasted state following a 10-hour overnight fast. Subjects randomized to Treatment B and Treatment D, as described below, were in the fed state, having had a high fat meal, completed ten minutes prior to dosing. There was a 14-day washout interval between the four dose administrations. The subjects were confined to the clinic during each study period. Subjects assigned to receive Treatment A and Treatment B were discharged from the clinic on Day 3 following the 48-hour procedures, and subjects assigned to receive Treatment C and Treatment D were discharged from the clinic on Day 2 following the 36-hour procedures. On Day 1 of each study period the subjects received one of four treatments:

Treatments A and B were of oxymorphone sustained release 20 mg tablets. Subjects randomized to Treatment A received a single oral dose of one 20 mg

oxymorphone sustained release tablet taken with 240 ml of water after a 10-hour fasting period. Subjects randomized to Treatment B received a single oral dose of one 20 mg oxymorphone sustained release tablet taken with 240 ml of water 10 minutes after a standardized high fat meal.

5            Treatments C and D were of oxymorphone HCl solutions, USP, 1.5 mg/ml injection 10 ml vials. Subjects randomized to Treatment C received a single oral dose of 10 mg (6.7 ml) oxymorphone solution taken with 240 ml of water after a 10-hour fasting period. Subjects randomized to Treatment D received a single oral dose of 10 mg (6.7ml) oxymorphone solution taken with 240 ml of water 10 minutes after a  
10        standardized high-fat meal.

A total of 28 male subjects were enrolled in the study, and 24 subjects completed the study. The mean age of the subjects was 27 years (range of 19 through 38 years), the mean height of the subjects was 69.6 inches (range of 64.0 through 75.0 inches), and the mean weight of the subjects was 169.0 pounds (range 117.0 through 202.0 pounds). The  
15        subjects were not to consume any alcohol-, caffeine-, or xanthine-containing foods or beverages for 24 hours prior to receiving study medication for each study period. Subjects were to be nicotine and tobacco free for at least 6 months prior to enrolling in the study. In addition, over-the-counter medications were prohibited 7 days prior to dosing and during the study. Prescription medications were not allowed 14 days prior to  
20        dosing and during the study.

The subjects were screened within 14 days prior to study enrollment. The screening procedure included medical history, physical examination (height, weight, frame size, vital signs, and ECG), and clinical laboratory tests (hematology, serum chemistry, urinalysis, HIV antibody screen, Hepatitis B surface antigen screen, Hepatitis  
25        C antibody screen, and a screen for cannabinoids).

During the study, the subjects were to remain in an upright position (sitting or standing) for 4 hours after the study drug was administered. Water was restricted 2 hours predose to 2 hours postdose. During the study, the subjects were not allowed to engage in any strenuous activity.

30            Subjects reported to the clinic on the evening prior to each dosing. The subjects then observed a 10-hour overnight fast. On Day 1, subjects randomized to Treatment B and Treatment D received a high-fat breakfast within 30 minutes prior to dosing. A standardized meal schedule was then initiated with lunch 4 hours postdose, dinner 10 hours postdose, and a snack 13 hours postdose. On Day 2, a standardized meal was

initiated with breakfast at 0815, lunch at 1200, and dinner at 1800. Subjects randomized to Treatment A and Treatment B received a snack at 2100 on Day 2.

Vital signs (sitting for 5 minutes and consisting of blood pressure, pulse, respiration, and temperature), and 12-lead ECG were assessed at the -13 hour point of each check-in period and at the completion of each period. A clinical laboratory evaluation (hematology, serum chemistry, urinalysis) and a brief physical examination were performed at the -13 hour of each check-in period and at the completion of the each period. Subjects were instructed to inform the study physician and/or nurses of any adverse events that occurred during the study.

Blood samples (7 ml) were collected during each study period at the 0 hour (predose), and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 20, 24, 30, 36, and 48 hours post-dose (19 samples) for subjects randomized to Treatment A and Treatment B. Blood samples (7 ml) were collected during each study period at the 0 hour (predose), and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 20, and 36 hours post-dose (21 samples) for subjects randomized to Treatment C and Treatment D. A total of 80 blood samples (560 ml) per subject were drawn during the study for drug analysis. Plasma samples were separated by centrifugation, and then frozen at -70°C, and kept frozen until assayed.

An LC/MS/MS method was developed and validated for the determination of oxymorphone in human EDTA plasma. Samples were spiked with internal standard, d<sub>3</sub>-oxymorphone, and placed on the RapidTrace® (Zymark Corporation, Hopkinton, MA) for automatic solid phase extraction. Extracts were dried under nitrogen and reconstituted with acetonitrile before injection onto an LC/MS/MS. The Perkin Elmer Sciex API III+, or equivalent, using a turbo ion spray interface was employed in this study. Positive ions were monitored in the MRM mode.

The pharmacokinetic parameters shown in Table 5 were computed from the plasma oxymorphone concentration-time data.

30

Table 5

AUC(0-t)	Area under the drug concentration-time curve from time zero to the time of the last quantifiable concentration (C <sub>t</sub> ), calculated using linear trapezoidal summation.
----------	--

AUC(0-inf)	Area under the drug concentration-time curve from time zero to infinity. $AUC(0-inf) = AUC(0-t) + C_t/K_{el}$ , where $K_{el}$ is the terminal elimination rate constant.
AUC(0-24)	Partial area under the drug concentration-time curve from time zero to 24 hours.
C <sub>max</sub>	Maximum observed drug concentration.
T <sub>max</sub>	Time of the observed maximum drug concentration.
K <sub>el</sub>	Elimination rate constant based on the linear regression of the terminal linear portion of the LN(concentration) time curve.
T <sub>1/2el</sub>	Half life, the time required for the concentration to decline by 50%, calculated as $LN(2)/K_{el}$

Terminal elimination rate constants were computed using linear regression of a minimum of three time points, at least two of which were consecutive.  $K_{el}$  values for which correlation coefficients were less than or equal to 0.8 were not reported in the pharmacokinetic parameter tables or included in the statistical analysis. Thus, T<sub>1/2el</sub>, AUC(0-inf), C<sub>1/F</sub>, MRT, and LN-transformed T<sub>1/2el</sub>, AUC(0-inf), and C<sub>1/F</sub> were also not reported in these cases.

A parametric (normal-theory) general linear model was applied to each of the above parameters (excluding T<sub>max</sub> and F<sub>rel</sub>), and the LN-transformed parameters C<sub>max</sub>, AUC(0-24), AUC(0-t), AUC(0-inf), C<sub>1/F</sub>, and T<sub>1/2el</sub>. Initially, the analysis of variance (ANOVA) model included the following factors: treatment, sequence, subject within sequence, period, and carryover effect. If carryover effect was not significant, it was dropped from the model. The sequence effect was tested using the subject within sequence mean square, and all other main effects were tested using the residual error (error mean square). The following treatment comparisons of relative rate and extent of absorption were made: Treatment B versus Treatment A, Treatment A versus Treatment C (dose normalized to 20 mg). Treatment B versus Treatment D (dose normalized to 20 mg), and Treatment D versus Treatment C (dose normalized to 20 mg for both treatments). The 90% confidence intervals of the ratios of the treatment least squares parameter means were calculated. T<sub>max</sub> was analyzed using the Wilcoxon Signed Ranks test. Summary statistics were presented for F<sub>rel</sub>.

Plasma oxymorphone concentrations were listed by subject at each collection time and summarized using descriptive statistics. Pharmacokinetic parameters were also listed by subject and summarized using descriptive statistics.

A total of 26 analytical runs were required to process the clinical samples from this study. Of these 26 analytical runs, 26 were acceptable for oxymorphone. Standard curves for the 26 analytical runs in EDTA plasma used in this study covered a range of 0.0500 to 20.000 mg/ml with a limit of quantitation of 0.0500 ng/ml for both compounds. Quality control samples analyzed with each analytical run had coefficients of variation less than or equal to 14.23% for oxymorphone.

A total of 28 subjects received at least one treatment. Only subjects who completed all 4 treatments were included in the summary statistics and statistical analysis.

The mean oxymorphone plasma concentration versus time curves for Treatments A, B, C, and D are presented in Figure 1 (linear scale, without standard deviation).

Individual concentration versus time curves were characterized by multiple peaks which occurred in the initial 12-hour period following the dose. In addition, a small "bump" in plasma oxymorphone concentration was generally observed in the 24 to 48 hour post-dose period.

The arithmetic means of the plasma oxymorphone pharmacokinetic parameters and the statistical comparisons for Treatment B versus Treatment A are summarized in Table 6.

TABLE 6

Summary of the Pharmacokinetic Parameters of Plasma Oxymorphone for Treatments B and A						
----- Plasma Oxymorphone -----						
Pharmacokinetic Parameters	Treatment A		Treatment B		90% CI	Mean Ratio
	Arithmetic Mean	SD	Arithmetic Mean	SD		
C <sub>max</sub> (ng/ml)	1.7895	0.6531	1.1410	0.4537	125.4-191.0	158.2
T <sub>max</sub> (hr)	5.65	9.39	5.57	7.14		
Auc(0-24)(ng*hr/ml)	14.27	4.976	11.64	3.869	110.7-134.0	122.3
AUC(O-t)(ng*hr/ml)	19.89	6.408	17.71	8.471	100.2-123.6	111.9
AUC(O-inf)(ng*hr/ml)	21.29	6.559	19.29	5.028	105.3-133.9	119.6
T <sub>1/2el</sub> (hr)	12.0	3.64	12.3	3.99	57.4-155.2	106.3

Treatment B = 1 x 20 mg oxymorphone sustained release Tablet, Fed: test

Treatment A = 1 x 20 mg oxymorphone sustained release Tablet, Fasted:  
reference

The arithmetic means of the plasma oxymorphone pharmacokinetic parameters  
and the statistical comparisons for Treatment A versus Treatment C are summarized in

5 Table 7.

**Table 7**

Summary of the Pharmacokinetic Parameters of Plasma Oxymorphone for Treatments A and C						
	----- Plasma Oxymorphone -----					
	Treatment A		Treatment C			
Pharmacokinetic Parameters	Arithmetic Mean	SD	Arithmetic Mean	SD	90% CI	Mean Ratio
Cmax(ng/ml)	1.1410	0.4537	2.2635	1.0008	33.4-66.0	49.7
Tmax(hr)	5.57	7.14	0.978	1.14		
Auc(0-24)(ng*hr/ml)	11.64	3.869	12.39	4.116	82.8-104.6	93.7
AUC(0-I)(ng*hr/ml)	17.71	8.471	14.53	4.909	107.7-136.3	122.0
AUC(0-inf)(ng*hr/ml)	19.29	5.028	18.70	6.618	80.2-108.4	94.3
T 1/2el(hr)	12.3	3.99	16.2	11.4	32.9-102.1	67.5

Treatment A = 1 x 20 mg oxymorphone sustained release Tablet, Fasted: test

Treatment C = 10 mg/6.7 ml oxymorphone HCl Oral Solution, Fasted: Dose

10 Normalized to 20 ng: reference.

The arithmetic means of the plasma oxymorphone pharmacokinetic parameters  
and the statistical comparisons for Treatment D versus Treatment C are summarized in

Table 8.

**Table 8**

Summary of the Pharmacokinetic Parameters of Plasma Oxymorphone for Treatments A and C						
	----- Plasma Oxymorphone -----					
	Treatment B		Treatment D			
Pharmacokinetic Parameters	Arithmetic Mean	SD	Arithmetic Mean	SD	90% CI	Mean Ratio
Cmax(ng/ml)	1.7895	0.6531	3.2733	1.3169	42.7-65.0	50.0
Tmax(hr)	5.65	9.39	1.11	0.768		
Auc(0-24)(ng*hr/ml)	14.27	4.976	17.30	5.259	74.4-90.1	82.2
AUC(0-t)(ng*hr/ml)	19.89	6.408	19.28	6.030	92.5-114.1	103.3
AUC (0-inf) (ng*hr/ml)	21.29	6.559	25.86	10.03	75.0-95.2	85.1
T 1/2el(hr)	12.0	3.64	20.6	19.3	31.9-86.1	59.0

Treatment B = 1 x 20 mg oxymorphone sustained release Tablet, Fed: test

Treatment D = 10 mg/6.7 ml oxymorphone HCl Oral Solution, Fed: Dose

Normalized to 20 mg: reference.

- 5 The arithmetic means of the plasma oxymorphone pharmacokinetic parameters and the statistical comparisons for Treatment D versus Treatment C are summarized in Table 9.

**Table 9**

Summary of the Pharmacokinetic Parameters of Plasma Oxymorphone for Treatments A and C						
	----- Plasma Oxymorphone -----					
	Treatment D		Treatment C			
Pharmacokinetic Parameters	Arithmetic Mean	SD	Arithmetic Mean	SD	90% CI	Mean Ratio
Cmax(ng/ml)	3.2733	1.3169	2.2635	1.0008	129.7-162.3	146.0
Tmax(hr)	1.11	0.768	0.978	1.14		
Auc(0-24)(ng*hr/ml)	17.30	5.259	12.39	4.116	128.5-150.3	139.4
AUC(0-t)(ng*hr/ml)	19.20	6.030	14.53	4.909	117.9-146.5	132.2
AUC (0-inf)(ng*hr/ml)	25.86	10.03	18.70	6.618	118.6-146.6	132.6
T 1/2el(hr)	20.6	19.3	16.2	11.4	87.3-155.9	121.6

- 10 Treatment D = 10 mg/6.7 ml oxymorphone HCl Oral Solution, Fed: Dose  
Normalized to 20 mg: test. Treatment C = 10 mg/6.7 ml oxymorphone HCl Oral  
Solution, Fasted: Dose Normalized to 20 mg: reference.

The relative bioavailability calculations are summarized in Table 10.

- 15 **Table 10:** Mean (S.D.) Relative Oxymorphone Bioavailability  
Determined from AUC (0-inf) and AUC (0-24)

	Frel BA		Frel AC		Frel BD		Frel DC	
AUC(0-inf)	1.169	(0.2041)	1.040	(0.1874)	0.8863	(0.2569)	1.368	(0.4328)
AUC(0-24)	1.299	(0.4638)	(0.9598)	(0.2151)	0.8344	(0.100)	1.470	(0.3922)

- 20 The objectives of this study were to assess the relative bioavailability of  
oxymorphone from oxymorphone sustained release (20 mg) compared to oxymorphone  
oral solution (10 mg) under both fasted and fed conditions, and to determine the effect of  
food on the bioavailability of oxymorphone from the sustained release formulation and  
from the oral solution.

The presence of a high fat meal had a substantial effect on the oxymorphone C<sub>max</sub>, but less of an effect on oxymorphone AUC from oxymorphone sustained release tablets. Least Squares (LS) mean C<sub>max</sub> was 58% higher and LS mean AUC(0-t) and AUC(0-inf) were 18% higher for the fed condition (Treatment B) compared to the fasted condition (Treatment A) based on LN-transformed data. This was consistent with the relative bioavailability determination from AUC (0-inf) since mean Frel was 1.17. Individual Frel values based on AUC (0-24) were similar (less than 20% different) to Frel values based on AUC (0-inf) for all but 2 subjects. Comparison of mean Frel from AUC (0-inf) to mean Frel from AUC (0-24) is misleading, because not all subjects had a value for AUC (0-inf). Mean T<sub>max</sub> values were similar (approximately 5.6 hours), and no significant difference in T<sub>max</sub> was shown using nonparametric analysis. Half value durations were significantly different between the two treatments.

The effect of food on oxymorphone bioavailability from the oral solution was more pronounced, particularly in terms of AUC. LS mean C<sub>max</sub> was 50% higher and LS mean AUC(0-t) and AUC(0-inf) were 32-34% higher for the fed condition (Treatment D) compared to the fasted condition (Treatment C) based on LN-transformed data. This was consistent with the relative bioavailability determination from AUC(0-inf) since mean Frel was 1.37. Individual Frel values based on AUC(0-24) were similar (less than 20% different) to Frel values based on AUC(0-inf) for all but 5 subjects. Comparison of mean Frel from AUC(0-inf) to mean Frel from AUC(0-24) is misleading because not all subjects had a value for AUC(0-inf). Mean T<sub>max</sub> (approximately 1 hour) was similar for the two treatments and no significant difference was shown.

Under fasted conditions, oxymorphone sustained release 20 mg tablets exhibited similar extent of oxymorphone availability compared to 10 mg oxymorphone oral solution normalized to a 20 mg dose (Treatment A versus Treatment C). From LN-transformed data, LS mean AUC(0-t) was 17% higher for oxymorphone sustained release, whereas LS mean AUC(0-inf) values were nearly equal (mean ratio=99%). However, AUC(0-t) is not the best parameter to evaluate bioavailability since the plasma concentrations were measured for 48 hours for the sustained release formulation versus 36 hours for the oral solution. Mean Frel values calculated from AUC(0-inf) and AUC(0-24), (1.0 and 0.96, respectively) also showed similar extent of oxymorphone availability between the two treatments.

There were differences in parameters reflecting rate of absorption. LS mean C<sub>max</sub> was 49% lower for oxymorphone sustained release tablets compared to the dose-



normalized oral solution, based on LN-transformed data. Half-value duration was significantly longer for the sustained release formulation (means, 12 hours versus 2.5 hours).

Under fed conditions, oxymorphone availability from oxymorphone sustained release 20 mg was similar compared to 10 mg oxymorphone oral solution normalized to a 20 mg dose (Treatment B versus Treatment D). From LN-transformed data, LS mean ~~AUC(0-inf) was 12% lower for oxymorphone sustained release. Mean Frel values~~ calculated from AUC(0-inf) and AUC(0-24), (0.89 and 0.83 respectively) also showed similar extent of oxymorphone availability from the tablet. There were differences in parameters reflecting rate of absorption. LS mean Cmax was 46% lower for oxymorphone sustained release tablets compared to the dose-normalized oral solution, based on LN-transformed data. Mean Tmax was 5.7 hours for the tablet compared to 1.1 hours for the oral solution. Half-value duration was significantly longer for the sustained release formulation (means, 7.8 hours versus 3.1 hours).

The presence of a high fat meal did not appear to substantially affect the availability following administration of oxymorphone sustained release tablets. LS mean ratios were 97% for AUC(0-t) and 91% for Cmax (Treatment B versus A), based on LN-transformed data. This was consistent with the relative bioavailability determination from AUC(0-24), since mean Frel was 0.97. AUC(0-inf) was not a reliable measure for bioavailability since half-life could not be estimated accurately, and in many cases at all. Half-life estimates were not accurate because in the majority of subjects, the values for half-life were nearly as long or longer (up to 2.8 times longer) as the sampling period. Mean Tmax was later for the fed treatment compared to the fasted treatment (5.2 and 3.6 hours, respectively), and difference was significant.

Under fasted conditions, oxymorphone sustained release 20 mg tablets exhibited similar availability compared to 10 mg oxymorphone oral solution normalized to a 20 mg dose (Treatment A versus Treatment C). From LN-transformed data, LS mean ratio for AUC (0-t) was 104.5%. Mean Frel (0.83) calculated from AUC(0-24) also showed similar extent of oxymorphone availability between the two treatments. There were differences in parameters reflecting rate of absorption. LS mean Cmax was 57% lower for oxymorphone sustained release tablets compared to the dose-normalized oral solution. Mean Tmax was 3.6 hours for the tablet compared to 0.88 for the oral solution. Half-value duration was significantly longer for the sustained release formulation (means, 11 hours versus 2.2 hours).

Under fed conditions, availability from oxymorphone sustained release 20 mg was similar compared to 10 mg oxymorphone oral solution normalized to a 20 mg dose (Treatment B versus Treatment D). From LN-transformed data, LS mean AUC(0-t) was 14% higher for oxymorphone sustained release. Mean Frel (0.87) calculated from AUC (0-24) also indicated similar extent of availability between the treatments. There were differences in parameters reflecting rate of absorption. LS mean Cmax was 40% lower for oxymorphone sustained release tablets compared to the dose-normalized oral solution. Mean Tmax was 5.2 hours for the tablet compared to 1.3 hour for the oral solution. Half-value duration was significantly longer for the sustained release formulation (means, 14 hours versus 3.9 hours).

The extent of oxymorphone availability from oxymorphone sustained release 20 mg tablets was similar under fed and fasted conditions since there was less than a 20% difference in LS mean AUC(0-t) and AUC(0-inf) values for each treatment, based on LN-transformed data. Tmax was unaffected by food; however, LS mean Cmax was increased 58% in the presence of the high fat meal. Both rate and extent of oxymorphone absorption from the oxymorphone oral solution were affected by food since LS mean Cmax and AUC values were increased approximately 50 and 30%, respectively. Tmax was unaffected by food. Under both fed and fasted conditions, oxymorphone sustained release tablets exhibited similar extent of oxymorphone availability compared to oxymorphone oral solution since there was less than a 20% difference in LS mean AUC(0-t) and AUC(0-inf) values for each treatment.

Bioavailability following oxymorphone sustained release 20 mg tablets was also similar under fed and fasted conditions since there was less than a 20% difference in LS mean Cmax and AUC values for each treatment. Tmax was later for the fed condition. The presence of food did not affect the extent of availability from oxymorphone oral solution since LS mean AUC values were less than 20% different. However, Cmax was decreased 35% in the presence of food. Tmax was unaffected by food. Under both fed and fasted conditions, oxymorphone sustained release tablets exhibited similar extent of availability compared to oxymorphone oral solution since there was less than a 20% difference in LS mean AUC values for each treatment.

Various modifications of the invention, in addition to those described herein, will be apparent to one skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

### Claims

What is claimed is:

1. A sustained release formulation comprising oxymorphone or a pharmaceutically acceptable salt thereof and a sustained release delivery system, wherein  
5 the sustained release delivery system comprises at least one hydrophilic compound, at least one cross-linking agent and at least one pharmaceutical diluent.
2. The sustained release formulation of claim 2, wherein the ratio of oxymorphone or a pharmaceutically acceptable salt thereof to the sustained release delivery system is from about 1:0.5 to about 1:25.
- 10 3. The sustained release formulation of claim 1, wherein the oxymorphone or pharmaceutically acceptable salt thereof is present in an amount of about 1 mg to about 200 mg in the formulation.
4. The sustained release formulation of claim 3, wherein the oxymorphone or pharmaceutically acceptable salt thereof is present in an amount of about 5 mg to  
15 about 80 mg in the formulation.
5. The sustained release formulation of claim 1, wherein the sustained release delivery system is present in an amount of about 80 mg to about 420 mg in the formulation.
6. The sustained release formulation of claim 5, wherein the sustained  
20 release delivery system is present in an amount of about 80 mg to about 360 mg in the formulation.
7. The sustained release formulation of claim 6, wherein the sustained release delivery system is present in an amount of about 80 mg to about 200 mg in the formulation.
- 25 8. The sustained release formulation of claim 1, wherein the at least one hydrophilic compound is present in the sustained release delivery system in an amount of about 20% to about 80% by weight; the at least one cross-linking agent is present in the sustained release delivery system in an amount of about 0.5% to about 80% by weight; and the at least one pharmaceutical diluent is present in the sustained release delivery  
30 system in an amount of about 20% to about 80% by weight.

9. The sustained release formulation of claim 8, wherein the at least one hydrophilic compound is present in the sustained release delivery system in an amount of about 20% to about 60% by weight; the at least one cross-linking agent is present in the sustained release delivery system in an amount of about 2% to about 54% by weight; and  
5 the at least one pharmaceutical diluent is present in the sustained release delivery system in an amount of about 20% to about 80% by weight.

10. The sustained release formulation of claim 9, wherein the at least one hydrophilic compound is present in the sustained release delivery system in an amount of about 40% to about 60% by weight; the at least one cross-linking agent is present in the  
10 sustained release delivery system in an amount of about 20% to about 30% by weight; and the at least one pharmaceutical diluent is present in the sustained release delivery system in an amount of about 40% to about 80% by weight.

11. The sustained release formulation of claim 1, wherein the at least one hydrophilic compound is a heteropolysaccharide gum.

15 12. The sustained release formulation of claim 1, wherein the at least one hydrophilic compound is at least one compound selected from xanthan gum, tragacanth gum, a pectin, acacia, karaya, agar, carrageenan, and a gellan gum.

13. The sustained release formulation of claim 1, wherein the at least one hydrophilic compound is a xanthan gum or a derivative thereof.

20 14. The sustained release formulation of claim 1, wherein the at least one cross-linking agent is a homopolysaccharide gum.

15. The sustained release formulation of claim 14, wherein the homopolysaccharide gum is a locust bean gum or a guar gum.

25 16. The sustained release formulation of claim 1, wherein the at least one pharmaceutical diluent is at least one compound selected from starch, lactose, dextrose, sucrose, microcrystalline cellulose, sorbitol, xylitol, and fructose.

17. The sustained release formulation of claim 1, wherein the ratio of the at least one hydrophilic compound to the at least one cross-linking agent is from about 1:9 to about 9:1.

18. The sustained release formulation of claim 1, wherein the ratio of the at least one pharmaceutical diluent to the at least one hydrophilic compound is from about 1:8 to about 8:1.
19. A method for treating a patient suffering from pain comprising  
5 administering an effective amount of the sustained release formulation of claim 1.
20. The sustained release formulation of claim 1, wherein the sustained release delivery system further comprises at least one hydrophobic polymer.
21. The sustained release formulation of claim 20, wherein the at least one hydrophobic polymer is present in the sustained release delivery system in an amount of  
10 about 0.5% to about 20% by weight.
22. The sustained release formulation of claim 21, wherein the at least one hydrophobic polymer is present in the sustained release delivery system in an amount of about 2% to about 10% by weight.
23. The sustained release formulation of claim 20, wherein the hydrophobic  
15 polymer is at least one compound selected from an alkylcellulose, a hydrophobic cellulosic material, a polyvinyl acetate polymer, a polymer or copolymer of acrylic and methacrylic acid esters, zein, a wax, a shellac and a hydrogenated vegetable oil.
24. The sustained release formulation of claim 23, wherein the alkyl cellulose is ethyl cellulose.
- 20 25. A method for treating a patient suffering from pain comprising administering an effective amount of the sustained release formulation of claim 20.
26. The sustained release formulation of claim 1, wherein the sustained release delivery system further comprises at least one cationic cross-linking compound.
27. The sustained release formulation of claim 26, wherein the at least one  
25 cross-linking compound is present in the sustained release delivery system in an amount of about 0.5% to about 30% by weight.
28. The sustained release formulation of claim 27, wherein the at least one cross-linking compound is present in the sustained release delivery system in an amount of about 5% to about 20% by weight.

29. The sustained release formulation of claim 26, wherein the at least one cationic cross-linking compound is at least one compound selected from a monovalent metal cation, a multivalent metal, cation, and an inorganic salt.

30. The sustained release formulation of claim 29, wherein the inorganic salt is an alkali metal sulfate, an alkali metal chloride, an alkali metal borate, an alkali metal bromide, an alkali metal citrate, an alkali metal acetate, an alkali metal lactate, an alkaline earth metal sulfate, an alkaline earth metal chloride, an alkaline earth metal borate, an alkaline earth metal bromide, an alkaline earth metal citrate, an alkaline earth metal acetate, an alkaline earth metal lactate, or a mixture thereof.

31. The sustained release formulation of claim 26, wherein the at least one cationic cross-linking compound is at least one compound selected from calcium sulfate, sodium chloride, potassium sulfate, sodium carbonate, lithium chloride, tripotassium phosphate, sodium borate, potassium bromide, potassium fluoride, sodium bicarbonate, calcium chloride, magnesium chloride, sodium citrate, sodium acetate, calcium lactate, magnesium sulfate, and sodium fluoride.

32. A method for treating a patient suffering from pain comprising administering an effective amount of the sustained release formulation of claim 26.

33. The sustained release formulation of claim 1, wherein the sustained release formulation has an *in vitro* dissolution rate of about 15% to about 50% by weight oxymorphone after about 1 hour.

34. The sustained release formulation of claim 1, wherein the sustained release formulation has as *in vitro* dissolution rate of about 45% to about 80% by weight oxymorphone after about 4 hours.

35. The sustained release formulation of claim 1, wherein the sustained release formulation has as *in vitro* dissolution rate of at least about 80% by weight oxymorphone after about 10 hours.

36. The sustained release formulation of claim 1, further comprising an outer coating, wherein the outer coating comprises at least one hydrophobic polymer.

37. The sustained release formulation of claim 36, wherein the hydrophobic polymer is at least one compound selected from an alkyl cellulose, a hydrophobic

cellulosic material, a polyvinyl acetate polymer, a polymer or copolymer of acrylic and methacrylic acid esters, zein, a wax, a shellac and a hydrogenated vegetable oil.

38. The sustained release formulation of claim 36, wherein the hydrophobic polymer is present on the sustained release formulation to a weight gain from about 1%  
5 to about 20% by weight.

39. The sustained release formulation of claim 1, further comprising an outer coating, wherein the outer coating comprises at least one plasticizer.

40. A sustained release formulation comprising oxymorphone or a pharmaceutically acceptable salt thereof and a sustained release delivery system, wherein  
10 the sustained release delivery system comprises at least one hydrophilic compound, at least one cationic cross-linking compound, and at least one pharmaceutical diluent.

41. The sustained release formulation of claim 40, wherein the ratio of oxymorphone or a pharmaceutically acceptable salt thereof to the sustained release delivery system is from about 1:0.5 to about 1:25.

42. The sustained release formulation of claim 40, wherein the oxymorphone or pharmaceutically acceptable salt thereof is present in an amount of about 1 mg to about 200 mg in the formulation.  
15

43. The sustained release formulation of claim 42, wherein the oxymorphone or pharmaceutically acceptable salt thereof is present in an amount of about 5 mg to about 80 mg in the formulation.  
20

44. The sustained release formulation of claim 40, wherein the sustained release delivery system is present in an amount of about 80 mg to about 420 mg in the formulation.

45. The sustained release formulation of claim 44, wherein the sustained  
25 release delivery system is present in an amount of about 80 mg to about 360 mg in the formulation.

46. The sustained release formulation of claim 45, wherein the sustained release delivery system is present in an amount of about 80 mg to about 200 mg in the formulation.

47. The sustained release formulation of claim 40, wherein the at least one hydrophilic compound is present in the sustained release delivery system in an amount of  
30

about 20% to about 80% by weight; the at least one cationic cross-linking agent is present in the sustained release delivery system in an amount of about 0.5% to about 30% by weight; and the at least one pharmaceutical diluent is present in the sustained release delivery system in an amount of about 20% to about 80% by weight.

5           48.     The sustained release formulation of claim 40, wherein the at least one hydrophilic compound is present in the sustained release delivery system in an amount of about 20% to about 60% by weight; the at least one cationic cross-linking agent is present in the sustained release delivery system in an amount of about 5% to about 20% by weight; and the at least one pharmaceutical diluent is present in the sustained release  
10 delivery system in an amount of about 20% to about 80% by weight.

          49.     The sustained release formulation of claim 48, wherein the at least one hydrophilic compound is present in the sustained release delivery system in an amount of about 40% to about 60% by weight; the at least one cationic cross-linking agent is present in the sustained release delivery system in an amount of about 5% to about 20%  
15 by weight; and the at least one pharmaceutical diluent is present in the sustained release delivery system in an amount of about 40% to about 80% by weight.

          50.     The sustained release formulation of claim 40, wherein the at least one hydrophilic compound is a heteropolysaccharide gum.

          51.     The sustained release formulation of claim 40, wherein the at least one  
20 hydrophilic compound is at least one compound selected from xanthan gum, tragacanth gum, a pectin, acacia, karaya, agar, carrageenan, and a gellan gum.

          52.     The sustained release formulation of claim 40, wherein the at least one hydrophilic compound is a xanthan gum or a derivative thereof.

          53.     The sustained release formulation of claim 40, wherein the at least one  
25 cationic cross-linking compound is at least one compound selected from a monovalent metal cation, a multivalent metal cation, and an inorganic salt.

          54.     The sustained release formulation of claim 53, wherein the inorganic salt is an alkali metal sulfate, an alkali metal chloride, an alkali metal borate, an alkali metal bromide, an alkali metal citrate, an alkali metal acetate, an alkali metal lactate, an  
30 alkaline earth metal sulfate, an alkaline earth metal chloride, an alkaline earth metal borate, an alkaline earth metal bromide, an alkaline earth metal citrate, an alkaline earth metal acetate, an alkaline earth metal lactate, or a mixture thereof.



55. The sustained release formulation of claim 40, wherein the at least one cationic cross-linking compound is at least one compound selected from calcium sulfate, sodium chloride, potassium sulfate, sodium carbonate, lithium chloride, tripotassium phosphate, sodium borate, potassium bromide, potassium fluoride, sodium bicarbonate, calcium chloride, magnesium chloride, sodium citrate, sodium acetate, calcium lactate, magnesium sulfate, sodium fluoride, and mixtures thereof.

56. The sustained release formulation of claim 40, wherein the at least one pharmaceutical diluent is at least one compound selected from starch, lactose, dextrose, sucrose, microcrystalline cellulose, sorbitol, xylitol, and fructose.

57. A method for treating a patient suffering from pain comprising administering an effective amount of the sustained release formulation of claim 40.

58. The sustained release formulation of claim 40, wherein the sustained release delivery system further comprises at least one hydrophobic polymer.

59. The sustained release formulation of claim 58, wherein the at least one hydrophobic polymer is present in the sustained release delivery system in an amount of about 0.5% to about 20% by weight.

60. The sustained release formulation of claim 59, wherein the at least one hydrophobic polymer is present in the sustained release delivery system in an amount of about 2% to about 10% by weight.

61. The sustained release formulation of claim 58, wherein the hydrophobic polymer is at least one compound selected from an alkyl cellulose, a polyvinyl acetate polymer, a polymer or copolymer derived from acrylic and methacrylic acid esters, zein, a wax, shellac and a hydrogenated vegetable oil.

62. The sustained release formulation of claim 61, wherein the alkyl cellulose is ethyl cellulose.

63. A method for treating a patient suffering from pain comprising administering an effective amount of the sustained release formulation of claim 58.

64. The sustained release formulation of claim 40, wherein the sustained release formulation has an *in vitro* dissolution rate of about 15% to about 50% by weight oxymorphone after about 1 hour.

65. The sustained release formulation of claim 40, wherein the sustained release formulation has as *in vitro* dissolution rate of about 45% to about 80% by weight oxymorphone after about 4 hours.

66. The sustained release formulation of claim 40, wherein the sustained  
5 release formulation has as *in vitro* dissolution rate of at least about 80% by weight oxymorphone after about 10 hours.

67. The sustained release formulation of claim 40, further comprising an outer coating, wherein the outer coating comprises at least one hydrophobic polymer.

68. The sustained release formulation of claim 67, wherein the hydrophobic  
10 polymer is at least one compound selected from an alkyl cellulose, a hydrophobic cellulosic material, a polyvinyl acetate polymer, a polymer or copolymer of acrylic and methacrylic acid esters, zein, a wax, a shellac and a hydrogenated vegetable oil.

69. The sustained release formulation of claim 67, wherein the hydrophobic polymer is present on the sustained release formulation to a weight gain from about 1%  
15 to about 20% by weight.

70. The sustained release formulation of claim 40, further comprising an outer coating, wherein the outer coating comprises at least one plasticizer.

71. A sustained release formulation comprising an inner core and an outer coating, wherein the inner core comprises oxymorphone or a pharmaceutically  
20 acceptable salt thereof and the outer coating comprises at least one hydrophobic polymer.

72. The sustained release formulation of claim 71, wherein the hydrophobic polymer is at least one compound selected from an alkyl cellulose, a hydrophobic cellulosic material, a polyvinyl acetate polymer, a polymer or copolymer of acrylic and methacrylic acid esters, zein, a wax, a shellac and a hydrogenated vegetable oil.

73. The sustained release formulation of claim 71, wherein the hydrophobic polymer is present on the sustained release formulation to a weight gain from about 1%  
25 to about 20% by weight.

74. The sustained release formulation of claim 71, wherein the outer coating further comprises at least one plasticizer.

75. The sustained release formulation of claim 71, wherein the outer coating  
30 further comprises at least one water soluble compound.

76. A method for treating a patient suffering from pain comprising administering an effective amount of the sustained release formulation of claim 71.

77. A sustained release formulation comprising from about 5 to about 80 mg oxymorphone hydrochloride and about 80 mg to about 360 mg of a sustained release delivery system; wherein the sustained release delivery system comprises about 8.3% to 41.7% by weight locust bean gum, about 8.3% to about 41.7% by weight xanthan gum, about 20% to about 55% by weight dextrose, about 5% to about 20% by weight calcium sulfate dihydrate, and about 2% to about 10% ethyl cellulose.

78. The sustained release formulation of claim 77, comprising about 20 mg oxymorphone hydrochloride.

79. The sustained release formulation of claim 77, comprising about 160 mg of a sustained release delivery system.

80. The sustained release formulation of claim 77, wherein the sustained release delivery system comprises about 25% locust bean gum, about 25% xanthan gum, about 35% dextrose, about 10% calcium sulfate dihydrate, and about 5% ethyl cellulose.

81. The sustained release formulation of claim 77, further comprising an outer coating.

82. A method for treating a patient suffering from pain comprising administering an effective amount of the sustained release formulation of claim 77.

83. A sustained release formulation comprising from about 5 to about 80 mg oxymorphone hydrochloride and about 300 mg to about 420 mg of a sustained release delivery system; wherein the sustained release delivery system comprises about 8.3% to 41.7% by weight locust bean gum, about 8.3% to about 41.7% by weight xanthan gum, about 20% to about 55% by weight dextrose, about 5% to about 20% by weight calcium sulfate dihydrate, and about 2% to about 10% ethyl cellulose.

84. The sustained release formulation of claim 83, comprising about 20 mg oxymorphone hydrochloride.

85. The sustained release formulation of claim 83, comprising about 360 mg of a sustained release delivery system.


86. The sustained release formulation of claim 83, wherein the sustained release delivery system comprises about 25% locust bean gum, about 25% xanthan gum, about 35% dextrose, about 10% calcium sulfate dihydrate, and about 5% ethyl cellulose.

87. The sustained release formulation of claim 83, further comprising an outer  
5 coating.

88. A method for treating a patient suffering from pain comprising administering an effective amount of the sustained release formulation of claim 83.

1/1

MEAN PLASMA OXYMORPHONE CONCENTRATIONS VERSUS TIME – LINEAR SCALE



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/21403

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 A61K31/485 A61K9/00 A61P25/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, EMBASE, SCISEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 01 08661 A (ROXANE LAB INC)            8 February 2001 (2001-02-08)</p> <p>page 6, last paragraph            page 13, paragraph FIRST            page 7, paragraph THIRD            claim 16            page 9, last paragraph            page 13, paragraph FIRST            page 11, paragraph FIRST            page 15-23</p> <p>--</p>	<p>1,2,            11-16,            19,20,            23-28,            32,36,            37,40,            41,            50-52;            56-58,            61-63,            67,68</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*S\* document member of the same patent family

Date of the actual completion of the international search

23 October 2002

Date of mailing of the international search report

31/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Brunnauer, H

## INTERNATIONAL SEARCH REPORT

In International Application No  
PCT/US 02/21403

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y A	----	1-76 77-88
X	WO 00 21520 A (SPITZLEY CHRISTOF ;WIMMER WALTER (DE); HAHN UDO (DE); BROEGMANN BI) 20 April 2000 (2000-04-20)  claims 1-3,9,11,12,14	1,19,20, 23-25, 33-37, 39,71, 72,74-76
Y A	----	1-76 77-88
Y	EP 0 636 366 A (EURO CELTIQUE SA) 1 February 1995 (1995-02-01) page 3, line 15-22 page 5, line 25-28 page 6, line 29-31 page 8, line 35 -page 9, line 1 page 9, line 27-41 page 12, line 20-23 page 10, line 30-37 page 10, line 52-58 page 12, line 42 page 15-28; examples 1-20	1-76
A	----	77-88
Y	US 5 965 161 A (CHASIN MARK ET AL) 12 October 1999 (1999-10-12) column 2, line 1-6 column 4, line 21 claims 3,9,10,60 column 7, line 20-23 column 7, line 34-37	1-76
A	-----	77-88

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 02/21403

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 19, 25, 32, 57, 63, 76, 82 and 88 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/21403

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0108661	A	08-02-2001	AU 6381300 A EP 1204406 A2 WO 0108661 A2	19-02-2001 15-05-2002 08-02-2001
WO 0021520	A	20-04-2000	DE 29818454 U1 AU 1039400 A WO 0021520 A2 EP 1121109 A2	14-01-1999 01-05-2000 20-04-2000 08-08-2001
EP 0636366	A	01-02-1995	US 5580578 A AU 686168 B2 AU 6868994 A CA 2128591 A1 EP 0636366 A2 US 6294195 B1 US 5639476 A US 5968551 A US 5958459 A US 6143353 A	03-12-1996 05-02-1998 09-02-1995 28-01-1995 01-02-1995 25-09-2001 17-06-1997 19-10-1999 28-09-1999 07-11-2000
US 5965161	A	12-10-1999	AU 705894 B2 AU 4157096 A AU 4736299 A CA 2204180 A1 EP 0785775 A1 HU 77626 A2 IL 115871 A JP 3186064 B2 JP 10508608 T KR 232945 B1 TW 425288 B WO 9614058 A1 US 2001033865 A1 US 6261599 B1 US 2001036476 A1 US 5958452 A ZA 9509367 A	03-06-1999 31-05-1996 28-10-1999 17-05-1996 30-07-1997 29-06-1998 17-08-1999 11-07-2001 25-08-1998 01-12-1999 11-03-2001 17-05-1996 25-10-2001 17-07-2001 01-11-2001 28-09-1999 13-06-1996